December 30, 2021

To Whom it may concern:

Bausch and Lomb Americas Inc. is providing the required information to the Office of the Attorney General regarding XIPERE™ (triamcinolone acetonide injectable suspension) 40 mg/mL pursuant to 18 V.S.A.§ 4637(c) (Notice of Introduction of New High-Cost Prescription Drugs). The Company previously provided notice of the introduction of this new drug pursuant to Sub-section (b) on December 2, 2021. As set forth in Sub-section (d), the manufacturer may limit the information reported pursuant to Sub-section (c) to that which is otherwise in the public domain or publicly available. Following the requirements, Bausch and Lomb Americas Inc. hereby reports the following:

- A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally – This information is not in the public domain or publicly available.

- The estimated volume of patients who may be prescribed the drug – There are an estimated 60,000 patients that suffer from uveitic macular edema. We do not know how many patients will be prescribed XIPERE™.

- Whether the drug was granted breakthrough therapy designation or priority review by FDA prior to final approval: No.

- The Date and Price of the acquisition if the drug was not developed by the manufacturer – The drug was not acquired.

Please note that as required, Bausch and Lomb Americas Inc. has completed the required report pursuant to 18 V.S.A.§ 4637 (Notice of Introduction of New High-Cost Prescription Drugs)

If you have any questions, please contact StatePriceReporting@BauschHealth.com